Gemfibrozil

What Is Gemfibrozil?

Gemfibrozil is a fibrate-class lipid-regulating medicine used primarily to treat hypertriglyceridaemia (significantly elevated triglyceride levels) and mixed dyslipidaemia (abnormal levels of multiple blood lipids). It is available under the brand name Lopid and is used when dietary measures and lifestyle changes alone have not been sufficient to bring triglyceride levels under control, or in patients at high cardiovascular risk who cannot tolerate statins or who require additional lipid-lowering beyond what a statin alone achieves.

Gemfibrozil works by activating peroxisome proliferator-activated receptor alpha (PPAR-alpha), a nuclear receptor that regulates the transcription of genes involved in lipid metabolism. This activation leads to increased clearance of triglyceride-rich lipoproteins (very low-density lipoproteins, or VLDLs), reduced hepatic triglyceride synthesis, and an increase in high-density lipoprotein (HDL) cholesterol — the so-called "good" cholesterol. Gemfibrozil also produces a modest reduction in LDL cholesterol in some patients, though its primary effect is on triglycerides and HDL.

Clinical Use and Evidence

Gemfibrozil is particularly effective in patients with severely elevated triglycerides (above 10 mmol/L), where the risk of acute pancreatitis is significant, and rapid lowering of triglyceride levels is a clinical priority. The Helsinki Heart Study demonstrated a significant reduction in coronary events in men with mixed dyslipidaemia treated with gemfibrozil, establishing its cardiovascular benefit. However, it is now less frequently used as a first-line agent than in previous decades, partly due to the risk of serious myopathy when combined with statins.

Lopid Brand

Gemfibrozil is most commonly prescribed as 600 mg tablets under the Lopid brand. The standard regimen involves taking one tablet twice daily, 30 minutes before meals, a timing requirement that helps optimise absorption and clinical effect. Patients starting gemfibrozil should also maintain a lipid-lowering diet and appropriate lifestyle measures, as medication alone cannot fully address the metabolic causes of elevated triglycerides.

How to Take Gemfibrozil

Gemfibrozil (Lopid) tablets should be taken 30 minutes before the morning and evening meals — this specific timing is important for optimal absorption and should be followed consistently. Each dose is 600 mg, taken twice daily. Tablets should be swallowed whole with a glass of water. Taking gemfibrozil at the same time each day helps maintain consistent blood levels and supports treatment adherence.

A lipid-lowering diet should be maintained throughout treatment. Reducing dietary fat, sugar, and alcohol is particularly important for managing hypertriglyceridaemia, as these dietary factors directly raise triglyceride levels. Patients with diabetes should ensure their blood glucose is well controlled, as hyperglycaemia significantly contributes to elevated triglycerides.

Monitoring During Treatment

Blood tests to assess triglycerides, HDL cholesterol, LDL cholesterol, and total cholesterol should be performed before starting treatment, at 3 months, and periodically thereafter to assess response. Liver function tests and creatine kinase (CK) levels should also be checked before and during treatment, as gemfibrozil can rarely affect liver enzymes and, more importantly, carries a risk of myopathy — particularly if combined with statins. Patients should report any unexplained muscle pain, tenderness, or weakness to their doctor without delay.

The standard adult dose of gemfibrozil is 600 mg taken twice daily, 30 minutes before breakfast and the evening meal, giving a total daily dose of 1200 mg. This dose has been established through clinical trials and is generally used without adjustment in most patients. In patients with mild to moderate renal impairment, the dose may need to be reduced, and gemfibrozil should be used with caution or avoided in severe renal impairment. There are no standard dose adjustments for elderly patients, but they should be monitored carefully given the increased risk of adverse effects. Gemfibrozil is not licensed for use in children. If a meaningful reduction in triglycerides has not been achieved after 3 months of treatment at the standard dose with adherence to diet, the appropriateness of continuing gemfibrozil should be reviewed by the prescriber.

Gemfibrozil is generally well tolerated, but a range of side effects can occur. Gastrointestinal symptoms are the most common complaints during the initial weeks of treatment and often improve over time.

Common Side Effects

• Dyspepsia (indigestion), stomach pain, nausea, or vomiting
• Diarrhoea or loose stools, especially in the early weeks of treatment
• Flatulence and abdominal bloating
• Headache and dizziness
• Rash, itching, or urticaria (hives)
• Fatigue and general malaise
• Raised liver enzymes (transaminases), which may be detected on blood tests

Serious Side Effects

• Myopathy and rhabdomyolysis: muscle pain, weakness, or swelling, particularly if gemfibrozil is taken alongside statins — this can cause life-threatening muscle breakdown and acute kidney injury; seek urgent medical attention if these symptoms develop
• Cholesterol gallstones: fibrates increase cholesterol excretion into bile, raising the risk of gallstone formation with long-term use
• Severe liver toxicity (hepatitis) in rare cases
• Blood dyscrasias including anaemia, leucopenia, or thrombocytopenia
• Pancreatitis (paradoxically, in very rare cases, despite being used to reduce pancreatitis risk in severe hypertriglyceridaemia)
• Peripheral neuropathy with prolonged use

Myopathy Risk and Statin Combination

Gemfibrozil carries a clinically significant risk of causing myopathy (muscle damage), and this risk is substantially increased when gemfibrozil is combined with statins. The combination of gemfibrozil with statins — particularly cerivastatin (withdrawn from the market partly for this reason), simvastatin, and other statins — should generally be avoided. Gemfibrozil inhibits the glucuronidation of statins in the liver, dramatically increasing statin blood levels and the risk of myopathy and rhabdomyolysis. If concurrent lipid-lowering therapy is clinically necessary, an alternative fibrate or alternative statin with a more favourable interaction profile should be discussed with a specialist.

Patients should be advised to report any unexplained muscle pain, cramps, or weakness immediately, and treatment should be discontinued if myopathy is suspected or if creatine kinase levels rise significantly.

Gallstones and Liver Function

Gemfibrozil increases the lithogenicity of bile (the tendency to form gallstones), and patients with a history of gallbladder disease should use it with caution. Liver function should be monitored periodically, and gemfibrozil should be discontinued if liver enzyme levels rise significantly above the upper limit of normal. Patients with hepatic disease should not take gemfibrozil. Alcohol consumption should be minimised, as it both raises triglyceride levels and places additional strain on the liver.

Gemfibrozil is contraindicated in the following circumstances:

• Hepatic impairment, including primary biliary cirrhosis and active liver disease
• Severe renal impairment or chronic kidney disease stage 4-5
• Pre-existing gallbladder disease or cholelithiasis (gallstones)
• Known hypersensitivity or allergy to gemfibrozil or related fibrates
• Concurrent use with repaglinide (gemfibrozil markedly increases repaglinide levels, risking severe hypoglycaemia)
• Concurrent use with dasabuvir (significant drug interaction)
• Concurrent use with statins where the combination poses an unacceptable myopathy risk
• Pregnancy and breastfeeding (safety not established; avoid unless benefits clearly outweigh risks)
• Children and adolescents under 18 years of age (not licensed for this age group)